Phenyl-3-(2-nitro-5-carbonsaeuremethylester)-thienylsulfid | 31845-06-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: Phenyl-3-(2-nitro-5-carbonsaeuremethylester)-thienylsulfid
• 英文别名: 5-nitro-4-phenylsulfanyl-thiophene-2-carboxylic acid methyl ester；Methyl 5-nitro-4-phenylsulfanylthiophene-2-carboxylate
• CAS: 31845-06-4
• 化学式: C₁₂H₉NO₄S₂
• 分子量: 295.34
• InChiKey: CAXDIJGBGMCGCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  126
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Phenyl-3-(2-nitro-5-carbonsaeuremethylester)-thienylsulfid 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-Benzenesulfonyl-5-nitro-thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s

  摘要：

  Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion injury, and acute transplant rejection. A series of arylsulfonylthiophene-2-carboximidine inhibitors of C1s were synthesized and evaluated for C1s inhibitory activity. The most potent compound had a K-i of 10 nM and >1000-fold selectivity over uPA, tPA, FXa, thrombin, and plasmin. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.036
• 作为产物：
  描述：

  4-溴-5-硝基噻吩-2-羧酸甲酯 、 苯硫酚 以 四氢呋喃 为溶剂， 生成 Phenyl-3-(2-nitro-5-carbonsaeuremethylester)-thienylsulfid
  参考文献：
  名称：

  A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s

  摘要：

  Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion injury, and acute transplant rejection. A series of arylsulfonylthiophene-2-carboximidine inhibitors of C1s were synthesized and evaluated for C1s inhibitory activity. The most potent compound had a K-i of 10 nM and >1000-fold selectivity over uPA, tPA, FXa, thrombin, and plasmin. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.036

文献信息

• A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s
  作者：Nalin L. Subasinghe、Jeremy M. Travins、Farah Ali、Hui Huang、Shelley K. Ballentine、Juan José Marugán、Ehab Khalil、Heather R. Hufnagel、Roger F. Bone、Renee L. DesJarlais、Carl S. Crysler、Nisha Ninan、Maxwell D. Cummings、Christopher J. Molloy、Bruce E. Tomczuk

  DOI：10.1016/j.bmcl.2006.01.036

  日期：2006.4

  Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion injury, and acute transplant rejection. A series of arylsulfonylthiophene-2-carboximidine inhibitors of C1s were synthesized and evaluated for C1s inhibitory activity. The most potent compound had a K-i of 10 nM and >1000-fold selectivity over uPA, tPA, FXa, thrombin, and plasmin. (C) 2006 Elsevier Ltd. All rights reserved.